The Administration &Outreach Core supports SPORE projects and investigators by managing SPORE resources, quality control, and communication and outreach, including fostering interaction among SPORE components and collaborators, other SPORES, the patient and advocate community, and the NCI. This management and support is accomplished through a series of oversight committees and organized administrative and scientific meetings of SPORE investigators, institutional representatives and external advisors. Specific functions of the Core include: To administratively manage and coordinate all SPORE-related research To monitor and manage financial resources To create and prepare documents and reports to ensure compliance with federal regulations and reporting requirements To administer the Developmental Research (pilot project) and Career Development Programs To organize all meetings, seminars, and travel related to Breast Cancer SPORE activities To serve as a point of contact to all VICC fundraising activities focused in breast cancer To support and coordinate all internal and external collaborations To serve as a main point of contact to biotechnology and pharmaceutical companies Carlos L. Arteaga, MD, and Jane Kennedy, MSSW, will serve as co-Directors of the Core. Arteaga reports directly to Jennifer Pietenpol, PhD, Director of VICC, and has input and assistance from the Deputy Director (Daniel Beauchamp, MD) and the Associate Directors for Basic Science (Scott Hiebert, PhD) and Cancer Epidemiology, Prevention &Control (William Blot, PhD). Arteaga provides advice to Dr. Pietenpol on programmatic directions and allocation of VICC resources for research in breast cancer. Since 2006, Ms. Jane Kennedy has served as Manager of Patient Advocacy in the VICC Office of Patient &Community Education (OPACE). Ms. Kennedy's role includes recruiting, training and coordinating the survivors and caregivers who contribute to and support the Research Advocacy Program of VICC, including the Breast SPORE.

Public Health Relevance

The Administration &Outreach Core supports SPORE projects and investigators by managing SPORE resources and finances, facilitating communications, coordinating outreach activities, fostering interactions (among SPORE components and collaborators, other SPOREs, the community and the NCI), and administering programmatic initiatives.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (M1))
Program Officer
Kuzmin, Igor A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
United States
Zip Code
Santos Guasch, Gabriela L; Beeler, J Scott; Marshall, Clayton B et al. (2018) p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion. iScience 8:236-249
Croessmann, Sarah; Sheehan, Jonathan H; Lee, Kyung-Min et al. (2018) PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K? Inhibitors. Clin Cancer Res 24:1426-1435
Elion, David L; Cook, Rebecca S (2018) Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. Oncotarget 9:29007-29017
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194
Luo, Na; Nixon, Mellissa J; Gonzalez-Ericsson, Paula I et al. (2018) DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun 9:248
Sudhan, Dhivya R; Schwarz, Luis J; Guerrero-Zotano, Angel et al. (2018) Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. Clin Cancer Res :
Werfel, Thomas A; Wang, Shan; Jackson, Meredith A et al. (2018) Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Cancer Res 78:1845-1858
Zhao, Shilin; Li, Chung-I; Guo, Yan et al. (2018) RnaSeqSampleSize: real data based sample size estimation for RNA sequencing. BMC Bioinformatics 19:191
Jia, Peilin; Zhao, Zhongming (2017) Impacts of somatic mutations on gene expression: an association perspective. Brief Bioinform 18:413-425

Showing the most recent 10 out of 341 publications